title: [Clinicopathological features and survival of bone metastasis from primary hepatic carcinoma].
abstract: OBJECTIVE
  To explore clinicopathological features and prognostic factors of bone metastasis from primary hepatic carcinoma (PHC).
  
  
  METHODS
  Eighty patients were enrolled with bone metastasis from PHC in Tianjin Medical University Cancer Institute and Hospital from January 2005 to June 2014 respectively. The clinicopathological features and prognostic factors of primary tumor were collected and bone metastases. Kaplan-Meier method was adopted for survival analysis. Log-rank method and Cox regression were used for univariate and multivariate analysis.
  
  
  RESULTS
  The median survival was 4.7 (95% CI range from 3.4 to 6.0) months. The 6-, 12-, and 24-month survival was 42.5%, 17.5%, 2.5%, respectively. Univariate analysis indicated that Child-Pugh grading (P<0.01), ECOG score (P=0.014), serum cholinesterase (P=0.002), total bilirubin (P=0.006), ascites (P=0.003), TACE (P<0.01) were significant prognostic factors of survival. Multivariate analysis revealed that Child-Pugh classification (P<0.01), TACE (P<0.01) were independent prognostic factors of survival.
  
  
  CONCLUSIONS
  Bone metastasis from PHC patients had poor survival. Patients can benefit from TACE and liver protecting treatment.
authors.affiliation: Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin 300060, China.
authors.forename: Yongfei
authors.initials: Y
authors.lastname: Guo
authors.affiliation: Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin 300060, China; Email: cjr.guozhi@vip.163.com.
authors.forename: Zhi
authors.initials: Z
authors.lastname: Guo
authors.affiliation: Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin 300060, China.
authors.forename: Haipeng
authors.initials: H
authors.lastname: Yu
authors.affiliation: Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin 300060, China.
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Sun
authors.affiliation: Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin 300060, China.
authors.forename: Xueling
authors.initials: X
authors.lastname: Yang
authors.affiliation: Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin 300060, China.
authors.forename: Weihao
authors.initials: W
authors.lastname: Zhang
mesh_terms: D001859:Bone Neoplasms; D006528:Carcinoma, Hepatocellular; D006801:Humans; D008113:Liver Neoplasms; D015999:Multivariate Analysis; D016019:Survival Analysis